Funding News

SBI Is Putting $1 Billion Into Sun Pharma's $11.75 Billion Organon Deal — India's Largest-Ever Outbound Pharma Acquisition Is Being Financed Like a Global Deal

By Mustafa Shariff, Editor in Chief · June 12,2026 · 2 min read

Summary

• Sun Pharma Acquires Organon for $11.75 Billion: India's Largest Outbound Pharma Deal and SBI's $1 Billion Financing Role
• Sun Pharma signed a $11.75 billion definitive agreement to acquire Organon in April 2026. SBI is now joining global lenders with a $1 billion commitment. Here is the full analysis of the deal.

"The deal enables Sun Pharma's entry into biosimilars as a top-10 global player. It will be a top 3 company in global Women's Health, creating a commercial platform for future growth, with 150-country presence and 18 large markets each generating over $100 million in revenue."

State Bank of India is preparing to join a consortium of global banks — Citigroup, JPMorgan Chase, and Mitsubishi UFJ Financial Group — in financing Sun Pharmaceutical Industries' $11.75 billion acquisition of Organon & Co., according to people familiar with the matter. SBI is set to commit as much as $1 billion, subject to board approval. The development, reported on June 10, 2026, has two distinct dimensions of significance: it advances the largest outbound pharmaceutical acquisition by an Indian company, and it marks one of the first major acquisition-financing roles by a government-run Indian bank following the Reserve Bank of India's February 2026 rule change that allowed domestic lenders to fund corporate takeovers.

Sun Pharma announced the definitive agreement to acquire Organon on April 27, 2026, at $14.00 per share in cash — a 24%-plus premium to Organon's pre-announcement trading price — with an enterprise valuation of $11.75 billion. The transaction is expected to close by December 2026, pending regulatory approvals from the US Department of Justice, European Commission, and other jurisdictions.

What Organon Is and Why Sun Pharma Wants It

Organon & Co. was spun off from Merck & Co. in June 2021 as an independent pharmaceutical company focused on women's health, biosimilars, and established brands. The spinoff was structured to give Merck a vehicle to separate its mature pharmaceutical portfolio — branded generics, off-patent specialty medicines — from its innovative drug pipeline, allowing each entity to pursue its own strategic direction.

Organon's three business segments are each strategically valuable to Sun Pharma in specific ways. The Women's Health segment — which includes contraceptives (Nexplanon, the globally leading subdermal contraceptive implant, and NuvaRing), fertility treatments (Follistim AQ, Elonva), and reproductive medicine products — establishes Sun Pharma as a top-3 global player in women's health. This is a category in which Indian pharmaceutical companies have historically had limited presence despite India having one of the world's largest women's health markets by patient volume.

The Biosimilars segment is equally transformative. Organon's biosimilar portfolio includes Hadlima (adalimumab biosimilar, approved in the US and Europe for inflammatory conditions), Renflexis (infliximab biosimilar), and a pipeline of additional biosimilar candidates. Sun Pharma's acquisition of Organon makes it the 7th largest biosimilar player globally — a position that would have taken a decade or more to build organically.

The Established Brands segment — a large portfolio of branded generic pharmaceutical products sold across emerging markets in the Middle East, Africa, Latin America, and Asia — adds scale in exactly the markets where Sun Pharma already has distribution infrastructure. The combined entity will have presence in 150 countries, with 18 markets each generating over $100 million in annual revenues.

The SBI Financing and Its Regulatory Significance

The Reserve Bank of India's February 2026 rule change — allowing Indian domestic banks to provide acquisition financing for cross-border corporate transactions — was a regulatory evolution long advocated by Indian industry. Prior to this rule change, Indian companies pursuing large overseas acquisitions were effectively forced to rely entirely on foreign banks for acquisition debt, placing them at a cost-of-capital disadvantage relative to companies in countries where domestic banks routinely participate in M&A financing.

SBI's commitment of up to $1 billion to the Sun Pharma-Organon financing consortium would be among the first major exercises of this new regulatory permission, and its scale — one billion dollars in a single transaction — signals that India's largest bank has appetite to be a meaningful participant in large Indian outbound deal financing rather than a token domestic presence.

The Combined Company's Profile

Upon completion of the acquisition, the combined Sun Pharma-Organon entity will have combined revenues of approximately $12.4 billion — placing it among the top 25 pharmaceutical companies globally. Of that revenue, approximately 27% will come from innovative medicines — a significant increase in Sun Pharma's innovation revenue share that reflects Organon's specialty pharmaceutical portfolio and pipeline assets.

BHC Perspective

At Bengaluru Health Community, the Sun Pharma-Organon acquisition is the most significant Indian pharmaceutical transaction of 2026 — and arguably in a decade. Combined with Wockhardt's Zaynich FDA approval (covered in our June 5 edition), it signals that Indian pharma is executing a genuine strategic transformation: from generics manufacturing to a position as a top-25 global pharmaceutical company with a balanced portfolio of women's health, biosimilars, and branded specialty products. For BHC founders in women's health, biosimilars, and specialty pharma — this deal reshapes the commercial and partnership landscape.

Frequently Asked Questions

Q: What is Sun Pharma acquiring?
A: Organon & Co. — a US-listed pharmaceutical company spun off from Merck in 2021, focused on women's health (Nexplanon, fertility drugs), biosimilars (Hadlima, Renflexis), and established brand pharmaceuticals. Enterprise value: $11.75 billion, at $14 per share in cash.

Q: How is the acquisition being financed?
A: Through a consortium of global banks: Citigroup, JPMorgan Chase, and MUFG — with State Bank of India now preparing to commit up to $1 billion, pending board approval. This would be one of the first major acquisition-financing roles by an Indian government bank following the RBI's February 2026 rule change.

Q: What does Sun Pharma become after this deal?
A: A top-25 global pharmaceutical company with $12.4 billion in combined revenues, top-3 in women's health globally, 7th largest biosimilar player, and presence in 150 countries with 18 markets each exceeding $100 million in revenues.